From the Analyst's Couch | Published:

Systemic lupus erythematosus

Nature Reviews Drug Discovery volume 8, pages 103104 (2009) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Lupus Foundation of America (LFA). Introduction to Lupus. LFA web site , (2008).

  2. 2.

    et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 58, 15–25 (2008).

  3. 3.

    Genentech. Genentech and Biogen Idec Announce Top-Line Results From Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus. Genentech web site , (2008).

  4. 4.

    FDA. FDA Warns of Safety Concern Regarding Rituxan in New Patient Population. FDA web site [online], , (2006).

Download references

Author information

Affiliations

  1. James Wentworth, Ph.D., is an Analyst in the Immunology & Inflammation team at Datamonitor Healthcare, 108-110 Finchley Road, London NW3 5JJ, UK.

    • James Wentworth
  2. Clare Davies, M.Eng., is Lead Analyst in the Immunology & Inflammation team at Datamonitor.

    • Clare Davies

Authors

  1. Search for James Wentworth in:

  2. Search for Clare Davies in:

Corresponding author

Correspondence to James Wentworth.

Supplementary information

PDF files

  1. 1.

    Supplementary information S1 (table)

    Products with PDUFA dates missed in 2008*

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrd2743

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing